Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced positive top-line results from its pivotal Phase 3 efficacy study of BEMA buprenorphine in opioid- “naive” subjects. BEMA buprenorphine is being developed for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy for an extended period of time in both patients who are opioid naive and opioid experienced. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) stock opened at $8.95 in last trading session, and closed at $9.41, trading in the range of $8.18 – $9.49. The stock showed a positive/negative weekly performance of 56.57%.
NanoString Technologies Inc (NASDAQ:NSTG), announced the pricing of its follow-on public offering of $55 million of its common stock at a price to the public of $18.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock. NanoString Technologies Inc (NASDAQ:NSTG) shares closed at $17.78 on last trade day, by losing -9.10%. Stock 52 week range is $7.01 – $20.79. Company’s market capitalization is $259.87 billion.
Emergent Biosolutions Inc (NYSE:EBS) announced the pricing of its offering of $215 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), which was upsized from the previously announced $200 million offering. Emergent also granted the initial purchasers an option to purchase up to an additional $35 million aggregate principal amount of the Notes. Emergent Biosolutions Inc (NYSE:EBS) stock decreased -2.97% and finished the last session at $22.85. The EPS of the stock remained 0.87. Company’s market capitalization is $830.99billion.
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Cleveland BioLabs, Inc. (NASDAQ:CBLI) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Cleveland BioLabs concerning the Company’s business and financial prospects. Cleveland BioLabs, Inc. (NASDAQ:CBLI) stock opened at $0.75 in last trading session and closed at $0.690. The 52 week range of the stock is $0.63 – $2.28 and the day range was $0.68 -$ 0.75.